Suppr超能文献

肥胖症和2型糖尿病中的11β-羟基类固醇脱氢酶1型

11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.

作者信息

Stulnig T M, Waldhäusl W

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine III, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

出版信息

Diabetologia. 2004 Jan;47(1):1-11. doi: 10.1007/s00125-003-1284-4. Epub 2003 Dec 3.

Abstract

Obesity and Type 2 diabetes mellitus are associated with abnormal regulation of glucocorticoid metabolism that are highlighted by clinical similarities between the sequelae of insulin resistance and Cushing's syndrome, as well as glucocorticoids' functional antagonism to insulin. 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activates functionally inert glucocorticoid precursors (cortisone) to active glucocorticoids (cortisol) within insulin target tissues, such as adipose tissue, thereby regulating local glucocorticoid action. Recent data, mainly from rodents, provide considerable evidence for a causal role of 11beta-HSD1 for the development of visceral obesity and Type 2 diabetes though data in humans are not unequivocal. This review summarizes current evidence on a possible role of 11beta-HSD1 for development of the metabolic syndrome, raising the possibility of novel therapeutic options for the treatment of Type 2 diabetes by inhibition or down-regulation of 11beta-HSD1 activity.

摘要

肥胖症和2型糖尿病与糖皮质激素代谢的异常调节有关,胰岛素抵抗后遗症与库欣综合征之间的临床相似性以及糖皮质激素对胰岛素的功能拮抗作用都凸显了这一点。11β-羟类固醇脱氢酶1型(11β-HSD1)在胰岛素靶组织(如脂肪组织)内将功能惰性的糖皮质激素前体(可的松)激活为活性糖皮质激素(皮质醇),从而调节局部糖皮质激素的作用。最近的数据(主要来自啮齿动物)为11β-HSD1在内脏肥胖症和2型糖尿病发展中的因果作用提供了大量证据,不过人类的数据并不明确。本综述总结了关于11β-HSD1在代谢综合征发展中可能作用的当前证据,提出了通过抑制或下调11β-HSD1活性来治疗2型糖尿病的新治疗选择的可能性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验